# CTNND2

Source: https://onco.cc/targets/ctnnd2/  
OnCo record `ctnnd2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CTNND2 (Catenin delta-2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma and 3 more.

## Summary

Has a critical role in neuronal development, particularly in the formation and/or maintenance of dendritic spines and synapses. Involved in the regulation of Wnt signalling. It probably acts on beta-catenin turnover, facilitating beta-catenin interaction with GSK3B, phosphorylation, ubiquitination and degradation.

IntOGen calls it a driver in 7 cohorts (5 activating, 2 loss-of-function), covering Oesophageal Adenocarcinoma, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Melanoma, Ovarian Epithelial Tumour, Pancreatic Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: catenin delta 2; Catenin delta-2; NPRAP; GT24
- Tags: cancer-genes-wave
- Symbol: CTNND2
- Class: transcription
- Biology: Has a critical role in neuronal development, particularly in the formation and/or maintenance of dendritic spines and synapses. Involved in the regulation of Wnt signalling. It probably acts on beta-catenin turnover, facilitating beta-catenin interaction with GSK3B, phosphorylation, ubiquitination and degradation. Functions as a transcriptional activator when bound to ZBTB33. May be involved in neuronal cell adhesion and tissue morphogenesis and integrity by regulating adhesion molecules. Location: Nucleus; Cell junction, adherens junction; Cell projection, dendrite; Perikaryon (UniProt). Locus 5p15.2 (HGNC).
- Where found: Oesophageal cancer: IntOGen driver in 1 cohort (ESCA); Ovarian cancer: IntOGen driver in 1 cohort (OVT); Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD); Non-small-cell lung cancer: IntOGen driver in 3 cohorts (LUAD, LUSC); Oesophageal and junctional adenocarcinoma: IntOGen driver in 1 cohort (ESCA); Melanoma: IntOGen driver in 1 cohort (MEL)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 5 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:2516: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2516
- UniProt Q9UQB3: https://www.uniprot.org/uniprotkb/Q9UQB3/entry
- NCBI Gene 1501: https://www.ncbi.nlm.nih.gov/gene/1501
- Ensembl ENSG00000169862: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169862

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/)
- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal and junctional adenocarcinoma](https://onco.cc/cancers/oesophageal-adenocarcinoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/ctnnd2.json